NSE: ABBOTINDIA | BSE: 500488

Falling Comet

Download real time

26170.00 100.00 (0.38%)

Near 52W Low of ₹25135.00

4,227 NSE+BSE Volume

NSE 16 Oct, 2026 3:31 PM (IST)

55,609.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

03 Sep 2026

26170.00

0.38%

Abbott India (BUY): Most brands in core portfolio growing healthilyAbbott India's core portfolio sales grew on both a sequential and yearly basis as of 1QFY27View Report

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Abbott India's core portfolio sales grew on both a sequential and yearly basis as of 1QFY27

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

13 May 2026

26170.00

0.38%

Abbott India (BUY): In line earnings; EBITDA Margin likely to sustain near its highs

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported -0.4%, -1.7%, -2.1% below our estimates. EBITDA Margin reported at 40 bps below our estimates

Abbott India Ltd. has an average target of 32579.67 from 3 brokers.

Abbott India Ltd.

12 May 2026

26170.00

0.38%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Direct

The company also markets some leading brands of Novo Nordisk and Abbott Healthcare for which it receives distribution margins. Some of the leading distributed brands- Human Mixtard, Ryzodeg, Novomix and...

Abbott India Ltd. has an average target of 32579.67 from 3 brokers.

Abbott India Ltd.

13 Feb 2026

26170.00

0.38%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Direct

New introduction tempo also maintained- Overall growth continues to be driven by legacy power brands (top 10 brands CAGR ~10% between January 23-26 despite slowdown in Mixtard and Novomix) and traction in few brands from the marketed portfolio. The company remains a standout performer among MNCs on the back of new products launch trajectory (+100 launches in the last 12 years and another 75 planned for the next 5 years) and performance consistency in most of the legacy brands. In FY25, the company introduced 7 new brands- Citrosoda UTI, Digene Insta,...

Abbott India Ltd. has an average target of 32579.67 from 3 brokers.

Abbott India Ltd.

27 Nov 2025

26170.00

0.38%

Abbott India (BUY): Visibility of margin improvement

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Mixtard 50 injectables off the shelf from Aug'25, yet monthly sales were Rs705 mn inAug'25, 762 mn in Sep'25 and Rs 710 mn in Oct'25

Abbott India Ltd. has an average target of 32579.67 from 3 brokers.

Abbott India Ltd.

09 Nov 2025

26170.00

0.38%

Operational leverage at play

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q2FY26 revenue grew at a modest pace of 7.6% YoY. We believe moderation in growth was mainly due to discontinuation of insulin pens for Human Mixtard, Levemir and Xultophy by Novo Nordisk in India as it prioritises capacity for GLP-1 brands Ozempic and Wegovy.

Abbott India Ltd. has an average target of 32579.67 from 3 brokers.

Abbott India Ltd.

08 Nov 2025

26170.00

0.38%

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Decent print driven by growth in some power brands- Revenues grew ~8% YoY to 1757 crore. As per IQVIA, some of the power brands such as Thyronorm (Hormonal), Udiliv (GI), Cremaffin Plus (GI) and Duphalac (GI) witnessed decent growth along with some marketed brands of Novo Nordisk and Abbott Healthcare such as Rybelsus (Semaglutide) and Ryzodeg (Insulin). While Mixtard (Insulin) and Novomix (Anti-Diabetic) registered de-growth during the quarter. EBITDA grew ~14% YoY to 502...

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

07 Nov 2025

26170.00

0.38%

Abbott India (BUY): Robust profitability amid GLP1 wave

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Sales reported 1.3% below while EBITDA/PAT reported 4.5%/6.4% above our estimates. EBITDA margin was 160 bps higher estimates

Number of FII/FPI investors increased from 105 to 120 in Sep 2026 qtr.

Abbott India Ltd.

17 Sep 2025, 12:00AM

26170.00

0.38%

Steady business, outpacing Pharma peers

Buy: Abbott India Ltd.

Target

Sharekhan

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.